Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications

Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications

Background: Pharmacogenomic testing, specifically for pharmacokinetic (PK) and pharmacodynamic (PD) genetic variation, may contribute to a better understanding of baseline genetic differences in patients seeking treatment for depression, which may further impact clinical antidepressant treatment rec...

Full description

Bibliographic Details
Main Authors: Marin Veldic, Ahmed T. Ahmed, Caren J. Blacker, Jennifer R. Geske, Joanna M. Biernacka, Kristin L. Borreggine, Katherine M. Moore, Miguel L. Prieto, Jennifer L. Vande Voort, Paul E. Croarkin, Astrid A. Hoberg, Simon Kung, Renato D. Alarcon, Nicola Keeth, Balwinder Singh, William V. Bobo, Mark A. Frye
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Pharmacology
Subjects:
pharmacogenomics
cytochrome P450
CYP2C19
SLC6A4
bipolar disorder
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00083/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00083/full

Similar Items